Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)

China flag China · Delayed Price · Currency is CNY
19.77
+0.23 (1.18%)
Mar 10, 2026, 2:04 PM CST
-20.67%
Market Cap 3.26B
Revenue (ttm) 574.88M
Net Income (ttm) 156.70M
Shares Out 166.80M
EPS (ttm) 0.94
PE Ratio 20.79
Forward PE 14.26
Dividend 0.20 (1.03%)
Ex-Dividend Date Jul 10, 2025
Volume 2,110,283
Average Volume 2,262,210
Open 19.58
Previous Close 19.54
Day's Range 19.50 - 19.85
52-Week Range 18.36 - 31.13
Beta 0.51
RSI 48.56
Earnings Date Apr 23, 2026

About Cabio Biotech (Wuhan)

Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products. The company was founded in 1999 and is based in Wuhan, the People’s Republic of China. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 574
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688089
Full Company Profile

Financial Performance

In 2025, Cabio Biotech (Wuhan)'s revenue was 574.88 million, an increase of 3.47% compared to the previous year's 555.59 million. Earnings were 156.70 million, an increase of 26.15%.

Financial Statements

News

There is no news available yet.